CD8 T-cell-mediated cerebellitis directed against Purkinje cell antigen after ipilimumab for small cell lung cancer

Neuropathol Appl Neurobiol. 2022 Feb;48(2):e12755. doi: 10.1111/nan.12755. Epub 2021 Aug 8.

Abstract

We report a rapidly progressive and fatal CD8 T-cell-mediated cerebellitis after ipilimumab (cytotoxic T-lymphocyte-associated protein 4 inhibitor) for small cell lung cancer. Clinical features and histopathology were consistent with an accelerated form of paraneoplastic cerebellar degeneration. A patchy CD8 T-cell infiltrate spatially corresponded to areas of Purkinje cell loss, with occasional CD8 polarisation towards Purkinje cells. CD20-positive B cells were sparse. CD8 T-cell-mediated cerebellitis after immune checkpoint inhibitor treatment may recapitulate the early stages of paraneoplastic cerebellar degeneration.

Keywords: CD8 T cells; CTLA-4 inhibitor; cerebellitis; immune checkpoint inhibitors; ipilimumab; paraneoplastic cerebellar degeneration.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD8-Positive T-Lymphocytes / immunology*
  • Humans
  • Immune Checkpoint Inhibitors / administration & dosage
  • Immune Checkpoint Inhibitors / adverse effects*
  • Immune Checkpoint Inhibitors / therapeutic use
  • Ipilimumab / administration & dosage
  • Ipilimumab / adverse effects*
  • Ipilimumab / therapeutic use
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / immunology
  • Lung Neoplasms / pathology
  • Male
  • Middle Aged
  • Paraneoplastic Cerebellar Degeneration / chemically induced*
  • Paraneoplastic Cerebellar Degeneration / immunology
  • Purkinje Cells / drug effects
  • Purkinje Cells / immunology*
  • Small Cell Lung Carcinoma / drug therapy*
  • Small Cell Lung Carcinoma / immunology
  • Small Cell Lung Carcinoma / pathology

Substances

  • Immune Checkpoint Inhibitors
  • Ipilimumab